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Abstract
Cytotoxic T Lymphocytes (CTLs) play a central role in controlling HIV-replication. Although numerous CTL epitopes have
been described, most are in subtype B or C infection. Little is known about CTL responses in CRF01_AE infection. Gag CTL
responses were investigated in a cohort of 137 treatment-naı ¨ve HIV-1 infected Thai patients with high CD4+ T cell counts,
using gIFN Enzyme-Linked Immunospot (ELISpot) assays with 15-mer overlapping peptides (OLPs) derived from locally
dominant CRF01_AE Gag sequences. 44 OLPs were recognized in 112 (81.8%) individuals. Both the breadth and magnitude
of the CTL response, particularly against the p24 region, positively correlated with CD4+ T cell count and inversely
correlated with HIV viral load. The breadth of OLP response was also associated with slower progression to antiretroviral
therapy initiation. Statistical analysis and single peptide ELISpot assay identified at least 17 significant associations between
reactive OLP and HLA in 12 OLP regions; 6 OLP-HLA associations (35.3%) were not compatible with previously reported CTL
epitopes, suggesting that these contained new CTL Gag epitopes. A substantial proportion of CTL epitopes in CRF01_AE
infection differ from subtype B or C. However, the pattern of protective CTL responses is similar; Gag CTL responses,
particularly against p24, control viral replication and slow clinical progression.
Citation: Mori M, Sriwanthana B, Wichukchinda N, Boonthimat C, Tsuchiya N, et al. (2011) Unique CRF01_AE Gag CTL Epitopes Associated with Lower HIV-Viral
Load and Delayed Disease Progression in a Cohort of HIV-Infected Thais. PLoS ONE 6(8): e22680. doi:10.1371/journal.pone.0022680
Editor: Johan K. Sandberg, Karolinska Institutet, Sweden
Received April 26, 2011; Accepted June 28, 2011; Published August 3, 2011
Copyright:  2011 Mori et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was mainly supported by the Japan Ministry of Health, Labour and Welfare; the Japan Foundation for AIDS Prevention and gCOE program,
Nagasaki University; and partly by the Ministry of Public Health, Thailand. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kari@nagasaki-u.ac.jp
Introduction
Cytotoxic T-Lymphocytes (CTLs) are an important component
of the adaptive immune system which mediate control of HIV
replication during acute infection and consequent viral set point
[1]. Numerous CTL epitopes have been reported across the HIV
proteome. However, the influence of CTL on clinical outcome
varies, as their recognition of viral antigen is restricted by highly
polymorphic class I Human Leukocyte Antigen (HLA) molecules
[2,3]. Furthermore, the tremendous degree of viral diversity
increases this complexity; to date, 13 prototype HIV clades and 43
circulating recombinant forms (CRF) have been described [4].
Some epitopes have been reported in a single clade; others have
been reported in multiple clades (cross-clade) [5,6]. No reported
epitope to date universally covers all HIV subtypes, or overcomes
the global variation in HLA allele distribution (CTL Epitopes. Los
Alamos National Lab. http://www.hiv.lanl.gov/).
Gag CTL responses, but not other CTL responses, have
consistently been reported to have a significant association with
viral control and clinical outcome [7]. However these findings
were derived mainly from African or Caucasian populations
infected with subtype C or B HIV, respectively; data from Asian
populations infected with subtypes circulating in south-east Asia,
such as CRF01_AE, have not yet been reported. To determine
whether a similar association exists in south-east Asian subtypes,
CTL epitope information is essential. However, as of April 2011,
only 26 of 420 known Gag epitopes have been reported in
CRF01_AE infection. Recently, the first successful phase III HIV
vaccine trial was reported from Thailand [8], although its efficacy
was marginal. For the development of a more effective vaccine, we
believe it is crucial to accurately understand the influence of
sequence variation amongst HIV subtypes, and HLA diversity
amongst ethnic groups. To provide more information about CTL
epitopes in CRF01_AE infection, we investigated cellular immune
responses to Gag overlapping peptides in an HIV-1 CRF01_AE-
infected Thai population and evaluated their impact on clinical
outcome.
Methods
Subjects
This study was approved by the Thai Ministry of Public Health
Ethics Committee and was conducted according to set guidelines
for research. Written informed consent was obtained after
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Patients were eligible for inclusion if they were chronically HIV-
infected and antiretroviral-naı ¨ve, with a CD4+ T cell count .200
cells/ul. A total of 137 HIV-1 CRF01_AE infected individuals
were recruited at a government referral hospital in Thailand from
October 2003 to May 2009. Study subjects were requested to visit
the clinic every 3 months and CTL responses were evaluated every
6 months. The study endpoint was initiation of antiretroviral
therapy, when their CD4+ T cell count declined below 200 cells/
ul.
Synthetic HIV-1 Gag overlapping peptides
Fifteen-mer overlapping peptides (OLPs) of locally dominant
CRF01_AE Gag sequences were designed based on 125 gag clonal
sequences derived from 45 CRF01_AE infected individuals
attending the clinic. All deduced amino-acid sequence data were
aligned and the most frequent 15-mer amino-acid sequence was
used as the dominant sequence.
Peptides were synthesized by Sigma Genosys (Hokkaido, Japan)
with a high purity of .90% as determined by high-pressure liquid
chromatography. In total, 98 peptides were synthesized and 20
pools were made by mixing 10 peptides per pool in a 10610
matrix design so that a single responsible peptide could be
identified by detecting the common peptide between two reactive
pools, as described previously [9–11]. When more than one
peptide was recognized, we further confirmed the responsible
peptide recognition by individually testing candidate peptides,
which were suspected by the matrix method.
ELISpot assay
1610
5 fresh PBMC/well were plated onto multiScreen plates
(MAHA54510; Millipore) that had been coated overnight at 4uC
with 50 ml of anti-gIFN capture Ab 1-D1-K (2 mg/ml; Mabtech,
Ohio, USA). Peptides were added directly to wells at a final
concentration of 1 mMi n5 0ml of R10 and incubated at 37uCi n
5% CO2 for 24 hrs. PBMC were stimulated with either medium
alone for negative control, 10 mg/ml phytohemagglutinin (PHA;
Sigma-Aldrich) for positive control or peptide (1 mM final
concentration) for 24 hrs at 37uC. Plates were washed extensively
with wash buffer (PBS/Tween20 0.001%), followed by incubation
with biotinylated anti-human gIFN mAb (0.5 mg/ml; clone 7-B6-
1; Mabtech) in PBS/10% FBS for 2 hrs at 37uC. Following six
further washes with wash buffer, 2 mg/ml streptavidin HRP
(Mabtech) was added to wells with 1 hr incubation at room
temperature. Spots were visualized using BCIP/NBT substrate
(Chemicon, Australia) and were counted using an Automated
Enzyme-Linked Immunospot (ELISpot) Reader System with KS
4.3 software by an independent scientist in a blinded fashion. Each
assay was undertaken in triplicate. Spot forming units (SFU) were
counted and expressed as SFU per million PBMCs, using the
average result from triplicate wells followed by subtraction of the
negative control values. A response was defined as positive if it was
three times higher than the negative control and greater than 150
SFU/1610
6 PBMC. The breadth of response was defined as the
total number of peptides recognized by each subject. The
magnitude of response for an individual was defined as the sum
of all positive peptide responses (in SFU/1610
6 PBMC). To avoid
overestimation of breadth or magnitude, two adjacent positive
overlapping peptides were counted as one response, using the
higher of the two responses.
HLA class I typing
Genomic DNA was extracted from buffy coat using the
QIAamp DNA blood Mini Kit (Qiagen, Hilden, Germany) and
4-digit HLA class I typing for A, B and Cw loci was undertaken by
bead-based array hybridization (WAKFlow HLA typing kit,
Wakunaga Pharmaceutical, Hiroshima, Japan) according to
manufacturer’s instructions at a commercial laboratory (Kyoto
HLA Laboratory, Kyoto, Japan).
Statistical analysis
Statistical analysis was performed using EXCEL 2007 and
SPSS. We first selected viral loads (VL) in the lowest (=q1) and
highest (=q4) quartiles (n=34 for each) and compared the
number of individuals with positive ELISpot responses to p17, p24
and p15 proteins, using Fisher’s exact test to compare groups. We
then analyzed the association between breadth and clinical
outcome (CD4+ T cell count and VL), using the Kruskal-Wallis
test, and between magnitude and clinical outcome (CD4+ T cell
count and VL) using Spearman’s correlation test. We also
performed a longitudinal analysis of the effect of breadth on
Highly Active Anti-Retroviral Therapy (HAART) initiation, using
the log rank test and Cox regression. For this analysis, the first
individual was enrolled on 6 July 2000 and the last individual on 4
September 2007, with a censoring date of 31 May 2009. Analysis
of OLP-HLA associations was undertaken using Fisher’s exact test
with 95% confidential intervals (CI). To have enough statistical
power, we analyzed OLP-HLA associations when OLPs were
recognized by 3 or more individuals with relevant HLA alleles and
at least in one individual, the OLP recognition was confirmed by
single peptide ELISpot experiments.
Results
Individuals’ background, including HLA distribution
Of 137 individuals recruited, 107 were female and 30 were
male. Median age was 31 years (range 16–56), CD4+ T cell count
461 cells/ul (range 204–1,191), and VL 4.22 log copies/ml (range
2.60–5.88). No individual had any HIV-related symptoms at the
time of enrollment. In total, 87 variations of HLA alleles were
found: 23 variations in HLA_A, 46 in HLA_B and 18 in HLA_Cw
in four digits (Table S1). Median duration of follow-up was 22
months (range 0–60) and ELISpot experiments were repeated
median 4 times (range 1–11) per individual. The peptide
recognition pattern was confirmed to be consistent on at least
two occasions for all except 24 individuals, in whom ELISpot
assays were undertaken only once. During the follow-up period,
the peptide recognition pattern did not change in any individual.
Gag OLP recognition and clinical outcome
Among 137 individuals, 112 (81.8%) recognized at least one
OLP. Of 98 OLPs, 44 (44.9%) were recognized by at least one
individual (Figure 1A): 12 peptides in p17, 26 in p24 and 6 in p15.
The second half of p24 (HXB2 261–360; OLP 52–69), was the
most highly targeted protein region; the first half of p17 (HXB2 5–
60; OLP 1–9) was the second most highly targeted region. 14
OLPs were recognized in one individual and the other 30 OLPs
were recognized in more than one individual. The most frequently
recognized peptides were all located in the second half of p24:
OLP 54 (HXB2 271–285), was recognized by 27 individuals; OLP
59 (HXB2 296–310) by 23 individuals; and OLP 66 (HXB2 331–
345) by 22 individuals.
To further elucidate the peptide recognition pattern that best
contributes to viral control, we next compared ELISpot responses
between two extreme VL groups: the lowest quartile (=q1)
(median VL 3.27 log copies/ml (range 2.60–3.71)) and the highest
quartile (=q4) (median 5.09 log copies/ml (range 4.76–5.88))
(Figure 1B). Median CD4+ T cell count was 515 cells/ul (range
Gag CTL Responses in CRF01_AE Infected Thais
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(p=0.022). Interestingly, individuals in q1 more frequently
recognized p24 peptides than those in q4 (29/34 vs 18/34,
respectively; p=0.0018, Fisher’s exact test), whereas individuals in
q4 tended to recognize p17 peptides more frequently (9/34 vs 12/
34, respectively; p=0.6), although this difference was not
significant.
ELISpot breadth, magnitude and clinical outcome
We next investigated the relationship between breadth and
clinical outcome. The CD4+ T cell count was significantly higher
in individuals with a greater breadth of response, with median
CD4+ T cell count of 409 cells/ul (range 204–995), 455 cells/ul
(range 243–793), 495 cells/ul (range 264–1,087) and 538 cells/ul
(range 303–1,191) in individuals with 0, 1, 2 and $3 responses,
respectively (p=0.018 by Kruskal-Wallis test) (Figure 2A left). VL
was significantly lower in individuals with a greater breadth of
response, with median VL of 4.83 log copies/ml (range 2.60–5.88),
4.21 log copies/ml (range 2.60–5.83), 4.26 log copies/ml (range
2.76–5.71) and 3.82 log copies/ml (range 2.60–5.04) in individuals
with 0, 1, 2 and $3 responses, respectively (p=0.0015) (Figure 2A
right). In a site-specific analysis, we did not find any significant
association with CD4+ T cell count in any sites (Figure 2B).
Interestingly, we found a significant association with VL only in
p24 (4.57 log copies/ml (range 2.60–5.88), 4.21 log copies/ml
(range 2.60–5.80), 4.17 log copies/ml (range 2.60–5.23) and 3.37
log copies/ml (range 2.60–4.14) in individuals with 0, 1, 2 and $3
responses, respectively; p=0.00028) but not in other sites
(Figure 2C).
We also found that magnitude of ELISpot response was
positively correlated with CD4+ T cell count (p=0.0032 by
Spearman’s correlation test y=0.031x+453 R
2=0.080) and
inversely correlated with VL (p=0.0084 y=20.0001x+4.41
R
2=0.055) (Figure 3A). In a detailed site-specific analysis,
magnitude in p24 had a significant correlation with clinical
outcome both in CD4+ T cell count (p=0.048 y=0.013x+493
R
2=0.010) (Figure 3B) and VL (p=0.0018 y=20.0001x+4.39
R
2=0.065) (Figure 3C), but not in other sites.
We next investigated the effect of breadth on clinical
progression using the initiation of antiretroviral therapy as the
end-point. During the follow-up period, 66/137 (48.2%) individ-
uals started antiretroviral therapy. Intriguingly, we found that
individuals with a wider breadth of CTL response were less likely
to start antiretroviral therapy than those with a narrower breadth
of response (Figure 4A, p=0.001 by log rank test): 18/25 (72.0%),
13/34 (38.2%), 30/57 (52.6%) and 5/21(23.8%) individuals with
0, 1, 2 and $3 responses, respectively, initiating antiretroviral
therapy. These data imply that strong CTL responses delay
Figure 1. Pattern of CRF01_AE Gag CTL responses. Frequencies of overlapping peptide (OLP) responses in 112 individuals are shown (A);
Frequencies of OLP responses in the lowest viral load group (lowest quartile, n=34) and the highest viral load group (highest quartile, n=34) were
compared (B).
doi:10.1371/journal.pone.0022680.g001
Gag CTL Responses in CRF01_AE Infected Thais
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e22680clinical progression by slowing the decline in CD4+ T cell count.
In a detailed site-specific analysis, individuals with a p24 response,
but not other responses, were significantly less likely to start
antiretroviral therapy than individuals without a p24 response
(p=0.001). However, the breadth of p24 response did not seem to
correlate with clinical progression (Figure 4B).
Multivariate analysis of the relationship between CTL response
and initiation of antiretroviral therapy, using Cox proportional
hazards model, showed that the association between breadth of
CTL response and initiation of HAART was independent of the
baseline CD4+ T cell count (.350 cells/ul or not) and VL (,4.0
log copies/ml, 4.0–4.9 log copies/ml and $5.0 log copies/ml):
adjusted Hazard Ratio (aHR) for individuals making $3 OLP
responses was 0.23 (p=0.005 with 95% CI of 0.08–0.64).
Detection of reactive OLP-HLA association
Associations between OLP responses and HLA were statistically
analyzed. In total, 14 peptides (4 in p17, 9 in p24 and 1 in p15)
with 31 OLP-HLA associations were identified (Table S2). 13
associations were found both with HLA-B and Cw alleles each and
Figure 2. ELISpot breadth is associated with CD4+ T cell count and viral load. The associations between ELISpot breadth (the number of
reacting OLP) and CD4+ T cell count or viral load were analyzed using the Kruskal-Wallis test (A). The p17, p24 or p15 site-specific ELISpot breadth was
also compared with CD4+ T cell count (B) and viral load (C); * and ** showed a significant difference of p,0.05(*) and p,0.01(**) by Mann-Whitney u-
test.
doi:10.1371/journal.pone.0022680.g002
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same responsible HLA allele: HLA_A*0207, B*4601 and
Cw*0102 in OLP 54–55, and B*4601 in OLP 58–59, suggesting
that CTL epitopes reside in the overlapping region of these
peptides. Some of the OLP-HLA associations may not reflect
genuine CTL epitopes. 10 OLP responses were associated with
two or more responsible HLA alleles. Of these, 9 OLP responses
were associated with a pair of HLA alleles in linkage disequilib-
rium (LD), which were identified using the Los Alamos database
(HLA Linkage Disequilibrium. Los Alamos National Lab. http://
www.hiv.lanl.gov/). Among the 10 OLP responses, 7 included
reported epitopes in either one of the HLA alleles. OLP 54, 55 and
59 responses were also associated with HLA alleles that have
haplotype associations: HLA_A*0207-B*4601-Cw*0102. In total,
11 OLP-HLA associations were compatible with previously
reported CTL epitopes: 4 epitopes were already reported as
cross-clade epitopes including CRF01_AE or subtype A and the
remaining 7 epitopes were reported in other subtypes but neither
in subtype A nor CRF01_AE. Consequently, we identified at least
17 OLP-HLA associations in 12 OLP regions; 6 OLP-HLA
associations (35.3%) were not compatible with previously reported
CTL epitopes, suggesting that these are likely to contain unique
CRF01_AE Gag CTL epitopes.
Discussion
This is the first study to investigate Gag CTL epitopes and their
effect on clinical outcome in a systematic way in a CRF01_AE-
infected Asian cohort. In this study, which tested optimal OLPs in a
well-described cohort, we succeeded in predicting a number of
unique CRF01_AE Gag epitope and novel cross-clade epitope
candidates. Although one third of CTL epitope candidates in
CRF01_AE infection were not compatible with previously reported
CTL epitopes in other subtypes, both cross-sectional and longitu-
dinal analysis showed the pattern of protective CTL responses was
similar to previous studies; specifically, that a Gag CTL response,
particularly against p24, was associated with better control of viral
replicationandslowerclinicalprogression[7,11–15].Thesefindings
are also compatible with our previous study in which an association
with clinical outcome was found only for the number of HLA-
associated mutations in p24 but not in other sites [16]. Both studies
imply that immune pressure on p24 Gag influences the clinical
outcome in CRF01_AE infected Asian individuals. Several papers
have discussedtheadvantagesofCTL immunepressure against p24
for viral control , which include selection of escape mutations that
lead to viral fitness cost [17,18], sequence stability compared with
other viral particles [4,19,20], the abundance of Gag protein in
incoming virions [21], and more rapid antigen presentation of Gag
epitopes following viral infection [18].
While our findings showed the clear-cut relationship between
ELISpot breadth and clinical parameters, the slopes of the trend
lines between ELISpot magnitude and clinical parameters were
rather shallow. Furthermore ELISpot magnitude did not correlate
with onset of HAART initiation. These findings are consistent
with a recently published study that breadth of the CTL response
rather than magnitude associated best with clinical outcome [22].
In this study, we could not detect any OLP-HLA associations in
HLA_B*57, which is well-known as one of the most protective
Figure 3. ELISpot magnitude is associated with CD4+ T cell count and viral load. The associations between ELISpot magnitude (total SFU
per 1.0 M PBMC) and CD4+ T cell count or viral load were analyzed by Spearman’s correlation (A). The p17, p24 or p15 site-specific response was also
compared with CD4+ T cell count (B) and viral load (C).
doi:10.1371/journal.pone.0022680.g003
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B*5701; however, none had any response to OLP 47, which
contains the TW10 (TSTLQEQIGW) epitope [24]. We have
previously found in our cohort that all B*57 patients had the
T242N escape mutation [16]. This suggests that the virus
circulating in B*57 individuals lacks the wild-type TW10 sequence
in vivo and no longer stimulates TW10 CTL cells [25].
In this study, OLP-HLA associations were predicted by
statistical analysis. Thus these associations are not necessarily a
reflection of new CTL epitopes with responsible HLA alleles. We
excluded LD associations, including haplotypes and adjacent
OLP responses with the same HLA allele association, in which
CTL epitopes presumably reside in the overlapping region of
these peptides. The most immunodominant OLP, number 54
(NKIVRMYSPVSILDI), was associated with three HLA alleles:
A*0207, B*4601 and Cw*0102. ‘‘RMYSPVSIL’’ was previously
identified as an A*0207-restricted CTL epitope [26]. All three
responsible HLA alleles were found to be in LD. However, the
association with B*4601 and Cw*0102 was much stronger than
for A*0207 (odds ratio 29.4 in B*4601 and 104 in Cw*0102 vs
5.5 in A*0207) and further analysis including by
51Cr release
assay is warranted.
From this study, we have substantially increased information
about CTL epitopes in CRF01_AE infection, reporting at least 6
unique CRF01_AE CTL epitope and 7 novel cross-clade epitope
candidates. CRF01_AE is a recombinant HIV-1 with Gag derived
from subtype A [4], from which CTL epitope information is
limited, compared to subtypes B or C. We anticipate that if a more
detailed epitope mapping study were to be conducted in subtype
A-infected populations, there would be a large number of epitopes
cross-recognized between CRF01_AE and subtype A.
Although details of OLP-HLA associations are substantially
different between subtypes, interestingly we found a similarity in
the immunodominant regions between subtypes. Our data showed
that the second half of p24 was the most immunodominant
regions, followed by the first half of p17 regions. This finding is
consistent with previous reports [13,15,27]. We were concerned
that the compatibility between OLP sequences and circulating
Gag sequences may vary depending on the conservativeness and
influence on the pattern of Gag CTL responses. However, the
proportion of gag clones that were completely matched to the
amino-acid sequence of OLPs was not associated with the
frequency of OLP responses (data not shown).
Cross-clade CTL responses are said to be influenced by the viral
sequence variability between subtypes, especially the sequence at
anchor positions of the HLA binding motif [4,28–31]. Among the
7 newly identified cross-clade epitope candidates, 6 shared the
same sequences with reported epitopes at both the B and F
pockets. We also compared sequence compatibility at the anchor
positions of the best-defined 12 epitopes, not identified in our
study. 11 out of 12 also had compatible sequences at anchor
positions, implying that sequence compatibility at anchor positions
per se does not predict cross-clade reactivity. Other factors should
be considered, such as sequences at flanking regions affecting
peptide cleavage by the proteasome [32,33] and epitope-HLA
complex recognition by T cell receptors (TCRs) [34,35].
Figure 4. ELISpot breadth is related to delayed initiation of antiretroviral therapy. The impact of ELISpot breadth on antiretroviral therapy
initiation was evaluated by Kaplan-Meier analysis, using the log rank test (A). The effect of p17, p24 or p15 site-specific ELISpot breadth was also
analyzed (B).
doi:10.1371/journal.pone.0022680.g004
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CTL immune responses and did not investigate whole viral
proteins. However, since this type of analysis requires a large
number of cells, and the volume of blood that we were able to take
was rather limited, we decided to focus on Gag responses, as Gag
is known to be the most important viral target. Instead of testing a
large number of OLPs individually, we undertook experiments in
triplicate, using a matrix system, to improve reliability. However, it
would have been ideal if we had obtained enough volume of blood
to confirm all responses using the individual peptides. Second, we
detected OLP-HLA associations by a statistical method and not by
the standard HLA-restriction analysis. This approach is easily
influenced by sample size and the impact of LD. Thus our study
does not provide direct evidence. Third, we have not yet
confirmed these OLP responses with CTL using the
51Cr release
assay. However, ELISpot assays are now widely accepted as a
technique for mapping CTL epitopes [36]. Fourth, these data are
based on single cytokine release of gIFN; we did not evaluate
multi-functionality of CTL with other cytokines such as IL2 or
TNFa [37].
However, our data indicate the existence of a substantial
number of unique CTL epitopes in CRF01_AE infection; it is
therefore worth conducting a systematic analysis of CTL epitopes
when vaccine trials are undertaken in different populations
infected with different subtypes.
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